NEW DELHI: Vice President M. Venkaiah Naidu discussed the status of the indigenous vaccine, Covaxin, with Bharat Biotech’s Director, Dr. Krishna Ella, and Joint Managing Director, Mrs Suchitra Ella. He also discussed plans to make it available in India and the rest of the world.
Covaxin is being developed by Bharat Biotech in collaboration with the Indian Council Medical Research (ICMR) – National Institute of Virology (NIC). The vaccine has drawn global attention, said ICMR.
“India’s indigenous vaccine against #COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves remarkable feat. Data generated from within India underlines impressive safety and immunogenicity profile of Covaxin and sparks Lancet’s interest in publishing them,” the ICMR tweeted.
“Encouraging Phase 1 and Phase 2 Covaxin trial results have paved the path for Phase 3 clinical trials in India, which is currently ongoing at 22 sites,” ICMR added.